Journal Club

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy

Volume 35, Issue 1, 3 January 2023, Pages 84-100.e8

Highlights

• Integrated analysis systematically demonstrates the ferroptosis heterogeneity in TNBC

• LAR subtype of TNBC is hypersensitive to ferroptosis inducers, especially GPX4 inhibitors

• AR plays a dual role in regulating ferroptosis of LAR tumors•Combination of GPX4 inhibitors and immunotherapy is an option for LAR tumors